MHRA responses





UPDATE 31 July 2010

A Trading Standards Officer has written to a UK supplier to notify them that the outcome of the consultation will be a ban of all ecigs which don't have applications for certification as medical devices.

The letter can be found HERE


2 August 2010 - The TS officer who wrote the letter has now retracted her claim that she knows the outcome of the consultation. http://ukvapers.com/topic/1675-it-looks-like-the-consultation-decision-h...








The UK Medicines and Healthcare Products Regulatory Agency have been conducting a public consultation (MLX 364) on The regulation of nicotine containing products. They want to introduce compulsory medical licensing for nicotine products with the exception of tobacco. As no ecig products have medical licenses this is simply a ban and would remove current commercial regulatory safeguards. A Banning Order is not being considered at the moment so unregulated supplies may be imported.

The consultation closed on 2nd June and the outcome is expected by September.








This is a report about the consultation from a UK government policy committee:


9 June 2010


OPINION


Consultation on regulation of nicotine containing products


Introduction

1. The Medicines and Healthcare products Regulatory Agency (MHRA), an executive agency of the Department of Health (DH), is consulting on introducing new regulations on nicotine containing products (NCPs) (excluding tobacco). At present any nicotine containing product that claims or implies that it can help with the cessation of smoking is considered a medicinal product by presentation and is regulated by MHRA (“regulation by claims”). These products are widely referred to as Nicotine Replacement Therapy (NRT). However, there are a number of NCPs, such as electronic cigarettes, which do not currently make such claims and hence are not regulated by MHRA.

2. MHRA believes that the regulation of all NCPs will “protect public health from products that have not been assessed for safety, quality and efficacy”. Any requirement for NCPs to be brought within medicine licensing would apply throughout the UK.

3. The RPC has looked at the quality of evidence and analysis provided in the consultation letter and accompanying impact assessment (IA) and, following a meeting with MHRA and DH, would like to make the following comments.


Summary Opinion

4. The RPC is of the opinion that the IA and consultation letter do not provide sufficient evidence to suggest that there is a significant risk to public health from currently unlicensed NCPs which would justify the future regulation of these products. MHRA should have made clearer what evidence is available to suggest there are safety and public health concerns about these products and considered a wider range of policy options before consulting on the introduction of a mandatory licensing requirement for all NCPs. In addition, the data and assumptions used in the IA for estimating the costs and benefits of the new regulations do not appear to be robust.


Detailed Opinion


Policy background and rationale

5. Following a recent review of its current policy on the application of the definition of a medicinal product in the context of nicotine and, after obtaining legal advice, MHRA has concluded that nicotine may potentially fall within medicines legislation because it affects human metabolism. MHRA is therefore proposing to regulate all NCPs (“regulation by function”), which means that all currently unlicensed products containing nicotine (excluding tobacco products) will either need to be removed from the market or licensed by a specific date. However, if MHRA considers changing its practice from regulating “based on claim” to a “regulation by function” principle, then it is not clear from the consultation letter how this will affect tobacco products (e.g. cigarettes), which also contain nicotine and hence will be within scope for these new regulations. MHRA has told the RPC that the tobacco products are excluded from this consultation as they have a separate regulatory regime and have no medicinal function.

6. It is not clear from the consultation letter or IA what specific policy problem MHRA is trying to address through the proposed new regulations. MHRA claims that the licensing of all NCPs is needed “in order to ensure there is no risk to public health from these products” (paragraph 18 of consultation letter). However, the evidence provided in the IA and consultation letter is not sufficient to conclude that there are serious risks to public safety and health to warrant regulatory intervention. In fact, the consultation letter itself acknowledges that the risk to the public health from NCPs is “unknown” (paragraph 17 of the consultation letter). MHRA has informed the RPC that there is potentially a legal obligation to licence these products. However, this issue is not clearly discussed and presented in the IA. The RPC also understands there is some limited evidence of potential harm from testing carried out by the US Food and Drug Administration.


Options

7. The IA considers two options in addition to the “do nothing” option. These two options both propose the regulation of all currently unlicensed NCPs, and the only difference between them is the proposed timeline for implementation of licensing requirements. It appears that Option 1, which provides a much shorter transition period (21 days) than Option 2 (implementation by June 2011), is preferred by MHRA on the grounds of being consistent with their current practice. In addition, the “do nothing” option is not developed because MHRA believes that “it is neither in the public health interest nor commercial interest to leave the current regulation of NCP/NRTs untouched” (paragraph 10 of the IA).

8. Subsequent to this the RPC believes that the range of options considered is too limited and the selection of the preferred option is not based on a robust appraisal of alternative options and their costs and benefits.


Costs and benefits

9. The data and assumptions used in the cost and benefit analysis of the IA do not seem to be robust. In the consultation letter MHRA acknowledges that the number of manufacturers of unlicensed NCPs and the number of products on the UK market are unknown. However, the IA estimates of costs and benefits are based on the assumption that there are 24 manufacturers and 50 products available on the UK market currently. However, the origin of these numbers is not provided and this raises concerns about the subsequent quality of cost estimates. MHRA has told the RPC that these estimates were based on the number of importers contacting the agency about licensing requirements. This needs to be clearly explained and presented in the IA.

10. MHRA estimates that there will be 1,312 additional permanent quitters of tobacco product users as a result of licensing of all NCPs. However, the assumptions and analysis behind this estimate do not appear to be supported by strong evidence. For example, the assumption that the proposed new regulations will bring a further 5% reduction in the number of individuals who permanently quit smoking using licensed NCPs per year is not based on a robust evidence and analysis.

11. Also, it is assumed that 50% of producers of currently unlicensed NCPs will obtain licences. It is not clear on what basis this assumption is made, nor is it clear why the cost of the remaining manufacturers and importers (for not being able to sell their products in the UK market) is not included in the cost estimates.


Impact on competition

12. The IA does not provide an appropriate assessment of the impact of the proposed regulations on competition. For example, the IA claims that all businesses will be equally affected by the regulations, while at the same time it assumes that at least 50% of manufacturers will be required to remove their products from the market as a consequence of the regulations.

13. The regulations are likely to create additional barriers for entry for new producers and importers of NCPs, which is not fully discussed in the IA. According to MHRA the European Commission has said that nicotine could fall within the medicines licensing regime. It is however not clear how consistent the proposed new regulations are with European Internal Market rules and how effectively they would be enforced to achieve their aims in this context.

14. The RPC is pleased to note that MHRA acknowledges the deficiencies in the existing analysis and evidence base, and the way the available evidence is presented in the consultation letter and the IA. The RPC hopes that these shortcomings will be addressed in the next version of the IA.


Michael J S Gibbons OBE

Chair

http://regulatorypolicycommittee.independent.gov.uk/rpc/wp-content/uploa...








Kate's response is attached, at the bottom of this page.


A great submission from e-cigs.co.uk


Ecigarettedirect.co.uk


Smartsmoker.co.uk have issued a response with some good legal arguments that may be relevant for all EU countries. It's attached to the bottom of this page.


ASH Scotland's submission
(They want recreational nicotine products except tobacco banned.)


No copy of ASH UK's response is available but they asked for compulsory licensing for non-tobacco nicotine products.


Royal Pharmaceutical Society


The Chartered Institute of Environmental Health








CASAA - Consumer Advocates for Smokefree Alternatives Association:

Theresa Whitt, M.D., Medical Director for The Consumer Advocates for Smoke-Free Alternatives Association (CASAA) says that ignoring the astounding 79% success rate of electronic cigarettes as replacements for tobacco cigarette smoking would be an abdication of the MHRA's mission to safeguard public health. CASAA wants the MHRA to exclude electronic cigarettes from its plan to step up regulation of nicotine-containing products.

Consumer Group Urges MHRA to Add E-Cigarettes to Harm Reduction Strategy

February 11, 2010: Mobile, Alabama

The Consumer Advocates for Smoke-Free Alternatives Association (CASAA) today called upon the Medicines and Healthcare products Regulatory Agency (MHRA) to exclude electronic cigarettes from its proposed regulatory framework, MLX 364, in view of the fact that 79% of regular users of an electronic cigarette have succeeded in using this product as a complete replacement for all their tobacco cigarettes. Electronic cigarettes are battery operated devices that vaporize a liquid that contains nicotine.

"As a result of eliminating their exposure to tobacco smoke, these consumers are experiencing significant improvement in their lung health and markers of cardiovascular health," stated Theresa Whitt, MD, CASAA Medical Director. "The 17% who have partially replaced their tobacco cigarettes are also reporting health improvements such as increased energy and improved sense of smell."

The statistics on the electronic cigarette success rate come from a survey conducted by the University of Alberta. There also have been recent news reports that, according to a poll conducted at Royal London Hospital, more than 50% of the people who stopped smoking during the past year preferred using the electronic cigarette. "If the MHRA doubts these statistics, it would take very little time and money for the agency to conduct their own survey to confirm or refute the findings," said Dr. Whitt. "But ignoring an astounding success rate like this, and taking action that might halt or reverse this positive outcome, would be an abdication of the MHRA's mission to safeguard public health."

"Recharacterizing the electronic cigarette as a medical product and regulating it as such stands to destroy its effectiveness as an alternative acceptable to smokers, Dr. Whitt continued. "One of the reasons that Nicotine Replacement Therapy, or NRT, products such as the nicotine patch, gum, lozenges, and inhalers have not worked for the majority of users is that the dose of nicotine is too low. The problem is then compounded when many revert to smoking as a result of discontinuing use of the NRT product."

The MHRA's Consultation Letter MLX 364 states "5% of smokers who quit using NRT remained quit after 8 years, and are assumed quit thereafter". Dr. Whitt believes that most, if not all, of the 79% who switched to electronic cigarettes will remain quit long-term, provided they can continue using their electronic cigarette.

"Many of those who have made the switch had no intention of quitting smoking," Dr. Whitt revealed. "But once they began using the electronic cigarette, they lost interest in lighting up a tobacco cigarette. In fact, many people report that when they attempt to smoke a regular cigarette again, they put it out after a puff or two because of the bad taste."

Dr. Whitt said that she believes the reason for the astonishing success rate of electronic cigarettes is that users can gear their nicotine intake to more closely match the nicotine level they used to obtain from smoking. Polls show that more than half of electronic cigarette users require a strength of 2.4% nicotine or higher, but less than 3% of users need a strength above 3.6% to stay off tobacco.

"Electronic cigarette consumers self-regulate their nicotine in the same way that tobacco smokers do, without much conscious thought," said Dr. Whitt. "They can increase or decrease the nicotine content in their cartridge, take more or fewer puffs, and adjust how they inhale. They determine their need for nicotine based on the same cues used by smokers: need for alertness, level of fatigue, mood, degree of stress, and state of muscular tension or relaxation."

Dr. Whitt pointed out that applying "Option 3 - Do nothing" to electronic cigarettes would not equate to lack of regulation. There are already regulations in place in the U.K. to ensure the quality and safety of electronic cigarette products. U.K. companies that distribute electronic cigarette liquid have had registered laboratories conduct toxicological testing. The companies have posted the results on their public web sites. So far, no tests have determined that electronic cigarette liquid or vapor contains harmful substances in quantities that would present a danger to human health.

"Of all the testing that has been conducted world-wide," stated Dr. Whitt, "the least useful has been the test conducted by the U.S. Food and Drug Administration (FDA). The FDA, enmeshed in a law suit with the two companies whose products were tested, made alarming announcements about carcinogens and toxins being detected. However, FDA failed to point out two important facts that would have placed their findings in the proper perspective: (1) the quantities of carcinogens in the liquid match the quantities in FDA-approved NRT products, and (2) all of the potentially harmful substances detected are present in tobacco smoke in quantities that are thousands of times larger."

"The biggest danger to human health would be the disappearance of electronic cigarettes as a much safer alternative to tobacco smoking," said Dr. Whitt. Dr. Whitt commended the MHRA for its efforts to pursue a tobacco harm-reduction approach, but added that she hoped that smoke-free alternatives such as Swedish snus and electronic cigarettes would be considered as part of the harm reduction strategy.

CASAA is a non-profit organization that works to ensure the availability of reduced harm alternatives to smoking and to provide smokers and non-smokers alike with truthful information about such alternatives. The association is headquartered in Mobile, Alabama USA, and has members from the U.S., Canada, and the U.K.

For further information:
The Consumer Advocates for Smoke-Free Alternatives Association
182 St Francis Street STE 300
Mobile, AL 36602
Elaine D. Keller
(703) 244-8692
ekeller@casaa.org








Dr Nitzkin:

20100214UKCommentMLX364.doc

Regulation of nicotine containing products as proposed will do more harm than good from a public health perspective. E-cigarettes, snus and at least selected other low-risk tobacco and tobacco-related products should be made as readily available as cigarettes to enable smokers unable or unwilling to quit to transition to a much lower risk product that is more satisfying and most likely more effective than the prescription NRT products currently available.

I am a public health physician. I, and the organization I represent have no financial interest in any E-cigarette or any other tobacco-related enterprise. Over the past three years, in my capacity as the Chair of the Tobacco Control Task Force of the American Association of Public Health Physicians I have carefully studied and been deeply involved in the debate on and and implementation by FDA of the new federal FDA/Tobacco law.

FDA's proposed action and statements against E-cigarettes -- claiming they might be as hazardous or more hazardous than conventional cigarettes and claiming they might result in the recruitment of large number of teens to nicotine addiction were based on a total lack of information and were totally speculative in nature. FDA staff, on the urging by some ill-informed tobacco control activists complained that E-cigarette companies had not applied for FDA approval as drug-device combinations. The E-cigarette companies did not due so because they considered their products tobacco-related products not covered by the drug law or regulations.

In mid January I personally met with Dr. Joshua Sharfstein - Deputy Director of the Food and Drug Administration and a number of his key medical and legal staff. I verbally presented the case in favor of regulating E-cigarettes as a tobacco product rather than a "drug-device combination" and the public health importance of informing current and potential tobacco users of the huge differences in risk presented by the different classes of tobacco products. Conventional cigarettes are the most hazardous of all tobacco products. E-cigarettes promise to be the nicotine delivery product most acceptable to smokers who are otherwise unable or unwilling to quit their nicotine addiction. Conventional cigarettes kill about 1/3 of smokers and large numbers of non-smokers exposed to environmental cigarette smoke. The risk posed by E-cigarettes, as best we can tell is about 0.1% (one tenth of one percent) of the risk posed by conventional cigarettes. They emit no environmental tobacco smoke.

On the basis of my presentation at FDA, I was invited to formally submit a citizens petition to FDA to formally present, in writing, the case in favor of both regulating E-cigarettes as a tobacco product, and the potential public health benefit of this action by FDA. This last week I put two such petitions in the mail to FDA, with 303 pages of attachments. The first petition asks FDA to do this reclassification. The second asks for a press conference to follow-up their July 22, 2009 press conference that left so many (including some in the State of Utah) to erroneously believe that E-cigarettes are more risky than conventional cigarettes. All these materials are readily available for review and download on the Tobacco Issues page of our http://www.aaphp.org web site.

Please feel free to contact me if you have any questions about this communication or the attached document.

Joel L. Nitzkin, MD








AttachmentSize
Kate's MHRA consultation response 4.doc1.44 MB
Smart Smoker submission.doc82.5 KB

Post new comment

  • Web page addresses and e-mail addresses turn into links automatically.
  • Allowed HTML tags: <a> <p> <span> <div> <h1> <h2> <h3> <h4> <h5> <h6> <img> <map> <area> <hr> <br> <br /> <ul> <ol> <li> <dl> <dt> <dd> <table> <tr> <td> <em> <b> <u> <i> <strong> <del> <ins> <sub> <sup> <quote> <blockquote> <pre> <address> <code> <cite> <embed> <object> <param> <strike> <caption> <tbody>
  • Lines and paragraphs break automatically.

More information about formatting options